Tango Therapeutics
TNGX
137 hedge funds and large institutions have $329M invested in Tango Therapeutics in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 27 closing their positions.
63% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 27
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
13% more funds holding
Funds holding: 121 → 137 (+16)
4.39% more ownership
Funds ownership: 94.7% → 99.09% (+4.4%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
58% less capital invested
Capital invested by funds: $781M → $329M (-$452M)
71% less call options, than puts
Call options by funds: $4K | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$49.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18.6M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$13M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
+$8.04M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$43.5M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
-$38.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.7M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$12.5M |
| 5 |
DM
Deerfield Management
New York
|
-$11.9M |
TNGX Hedge Fund Activity: Q4 2024 in Review
137 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q4 2024, worth a combined $329M — down 58% from $781M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new TNGX positions and 27 closed out — a net gain of 17 holders — while 40 added to existing stakes and 28 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $49.8M. The largest seller was Fidelity Investments, cutting an estimated $43.5M.
- 137 institutional investors held Tango Therapeutics (TNGX) as of Q4 2024, up from 121 in Q3 2024.
- Funds reported $329M of Tango Therapeutics stock for Q4 2024, down 58% quarter-over-quarter.
- 44 funds opened new Tango Therapeutics positions in Q4 2024 and 27 closed out, a net change of +17 holders.
- The largest Tango Therapeutics buyer in Q4 2024 was TCG Crossover Management, an estimated $49.8M added.
- The largest Tango Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $43.5M sold.
Based on aggregated 13F filings for Q4 2024.